Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma.

by Quan Wang, Feng Wei, Chunsheng Li, Guoyue Lv, Guangyi Wang, Tongjun Liu, Anita C Bellail, Chunhai Hao
Published 2013-01-01